Description

With extensive updated information on everything from treatment of hypertension to orphan drugs, AHFS® Drug Information® 2019 Edition is a necessary addition to your pharmacy’s resources.

With expanded and revised content supported by more than 92,000 references and incorporating the advice of numerous subject matter experts, AHFS® DI® helps you protect your patients and your practice. It’s the only print compendium designated by the U.S. Congress, the only compendium published by a professional and scientific society, and is the reference that has been trusted by pharmacists and other healthcare professionals for over 60 years.

AHFS® DI® contains the most trustworthy drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

Updates for this edition include:

• • Important updated monographs and references related to revised therapeutic guidelines, including revised recommendations for treatment of hypertension, including discussions of controversies in blood pressure threshold for initiating antihypertensive drug therapy and specific treatment goals
• • Newly published information on breakthrough oncology drugs approved as part of the FDA’s accelerated approval program
• • Coverage of the 2018-2019 recommendations from the Institute for Safe Medication Practices (ISMP) on targeted medication safety best practices for hospitals
• • Information about vaccines and other immunizing agents, including recommendations for travelers

Drug monographs in AHFS DI are thoroughly researched by drug information pharmacists and professional editorial and analytical staff. Authors incorporate clinical research findings, guidelines, and FDA-approved labeling into the monographs. The information also reflects the expertise of leading medical scientists, physicians, pharmacists, pharmacologists, and other clinicians, and incorporates the latest therapeutic recommendations from groups like the US Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), the American Academy of Pediatrics, the American Heart Association, and many others.

This title updates: Monthly

Doody's Reviews

Quotes, Reviews or Testimonials

"This reference is widely used and trusted for its established record in refuting unfounded efficacy claims, its rigorous science-based editorial process, and its independence from the influence of pharmaceutical manufacturers."

-- Jennifer Colon, PharmD, MS, MBA (Temple University School of Pharmacy) - previous edition

"You cannot be a pharmacist without this book. For clinical pharmacists especially it is the standard..."

-- Miriam Klein, Pharm.D. R.Ph. (Woodhull Medical Center) - previous edition

“AHFS Drug Information is by far the most comprehensive and informative drug reference that I use. It offers much more in-depth information and post-marketing [after FDA approval] analysis on drugs.”

-- Jay S. Cohen, M.D., Associate Professor of Family and Preventive Medicine, University of California at San Diego Medical School - previous edition

“There is more in-depth information in AHFS DI, particularly pharmacology and kinetics. At times I especially need the unlabeled uses in AHFS Drug Information to answer questions. Other references don't include as many off-label uses.”

-- Paul Matuschka, Pharm.D., VA Medical Center, Louisville, KY - previous edition

Audience

This reference is intended to shape treatment decisions made by practitioners and clinicians and to influence public and private healthcare policies and decisions. It can be used as a valuable and unbiased pharmaceutical reference by clinical students and practitioners.

Table of Contents

Similar Resources